Navigation Links
Scientists bioengineer a protein to fight leukemia
Date:2/18/2011

LOS ANGELES (February 18, 2011) Scientists at the Children's Center for Cancer and Blood Diseases and The Saban Research Institute of Children's Hospital Los Angeles today announced a breakthrough discovery in understanding how the body fights leukemia. They have identified a protein called CD19-ligand (CD19-L) located on the surface of certain white blood cells that facilitates the recognition and destruction of leukemia cells by the immune system. This work represents the first report of a bioengineered version of CD19-L, a recombinant human biotherapeutic agent, targeting CD19-positive leukemic stem cells.

B-lineage acute lymphoblastic leukemia (ALL) is the most common cancer occurring in children and adolescents. Despite having received intensive chemotherapy, some patients have recurring disease. For these individuals, the prospect of long-term survival is poor.

"We need new anti-leukemia therapies capable of killing chemotherapy-resistant leukemia cells in patients with relapsed ALL. These are the cells that are the most difficult to treat. The challenge is to kill these cells while leaving healthy cells intact," said Fatih Uckun, MD, PhD, first author on the paper that has been published in the British Journal of Haematology. Dr. Uckun is also a professor of Pediatrics at the University of Southern California Keck School of Medicine and a member of the Developmental Therapeutics Program at the Norris Comprehensive Cancer Center.

Lymphocytes are a type of white blood cell involved in immune function and are categorized as either B-cells or T-cells. This newly discovered element, CD19-L, is expressed on the surface of T-lymphocytes and allows them to selectively bind to the CD19 receptor on the surface of B-lineage leukemia cells, and most importantly on leukemic stem cells responsible for the survival and expansion of the leukemia cell population. Once the CD19-L binds to leukemia cells, cell death occurs. Although CD19 is abundantly expressed on leukemia cells from B-lineage ALL patients, it is absent on red cells, T-cells, and normal bone marrow stem cells, making it specific, and therefore, a good therapeutic target.

Dr. Uckun and colleagues have bioengineered and prepared a highly purified liquid formulation of the human CD19-L protein. This recombinant protein not only shows selective binding to leukemia cells but also causes their rapid destruction within 24 hours. Perhaps most importantly, CD19-L killed even those leukemia cells that were highly resistant to both standard chemotherapy drugs as well as radiation.

CD19-L is the first CD19-specific recombinant human protein with potent anti-leukemic activity against B-lineage ALL, the most common form of childhood cancer and the second most common form of acute leukemia in adults. The identification of CD19-L may lead to therapeutic innovation for childhood leukemia by allowing a selective destruction of leukemic stem cells. According to Dr. Uckun, the next step will be to carefully evaluate this new agent for clinical potential against leukemia and to confirm in preclinical studies that leukemic cell destruction can be achieved at non-toxic dose levels.

"The CD19-ligand offers a previously unrecognized defense system against leukemia and opens a new range of therapeutic opportunities for the treatment of leukemia," said Stuart Siegel, MD, director of the Center for Cancer and Blood Diseases at Childrens' Hospital Los Angeles.


'/>"/>

Contact: Ellin Kavanagh
ekavanagh@chla.usc.edu
323-361-8505
Children's Hospital Los Angeles
Source:Eurekalert  

Related medicine news :

1. Saint Louis U scientists partner on malaria research
2. Firefly glow: Berkeley Lab scientists develop a hydrogen peroxide probe based on firefly luciferin
3. A guide star lets scientists see deep into human tissue
4. Scientists develop method to identify fleetingly ordered protein structures
5. Scripps Research scientists develop powerful new methodology for stabilizing proteins
6. Princeton scientists discover mechanism involved in breast cancers spread to bone
7. Scientists Discover Rare Vascular Disease
8. Scientists ID Genetic Clues to Parkinsons
9. Southampton scientists begin patient trials of new leukemia cancer vaccine
10. Scientists find key protein that suppresses prostate cancer growth in the laboratory
11. Victor Chang scientists unlock the gates on sudden cardiac death
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Scientists bioengineer a protein to fight leukemia
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Apple ... care services, staged a mock evacuation of the facility as part of a disaster ... Fire Department, Echo Hose EMS and Shelton City Emergency Manager, as well as the ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Global Healthcare Management’s ... Alexandria Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s ... The fun run is geared towards children of all ages; it is a ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the ... danger possible to save lost souls in the Philippines. “The Journey: From the Mountains ... a dedicated teacher of the Bible. She has taught all ages and currently teaches ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the largest and ... plans to open a flagship location in Covington, LA at 401 N. U.S. Highway ... store next to Office Depot in the Holiday Square shopping center. Its location allows ...
(Date:10/12/2017)... ... 2017 , ... Asante, a nationally recognized health system in ... existing home health joint venture through an agreement, effective October 1, 2017, to ... home health company with Asante, delivering clinically integrated care, for the past eight ...
Breaking Medicine News(10 mins):
(Date:10/10/2017)... -- NDS received FDA 510(k) clearance in May 2017 for its highly ... designed for endoscopy environments. An innovative secondary monitor solution, ZeroWire ... support the improvement of patient outcomes, procedural efficiency, and the lowering ... ... ...
(Date:10/4/2017)... 4, 2017  South Korean-based healthcare product Development Company ... "cprCUBE" on Kickstarter. The device will educate the user ... with better efficiency compared to the dated and pricey ... on efficacy of the compression for a more informed ... goal to raise $5,000. ...
(Date:10/2/2017)... 2017  Eli Lilly and Company (NYSE: ... third quarter of 2017 on Tuesday, October 24, 2017. ... day with the investment community and media to further ... call will begin at 9 a.m. Eastern time. Investors, ... webcast of the conference call through a link that ...
Breaking Medicine Technology: